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Abstract 
Covalent attachment of one or more ubiquitin molecules to protein substrates governs 
numerous eukaryotic cellular processes including apoptosis, cell division and immune 
response. Ubiquitylated proteins can be targeted for degradation but ubiquitylation 
also mediates processes such as protein-protein interactions and cell signalling, 
depending on the type of ubiquitin conjugation. Ubiquitin ligases (E3s) catalyze the 
final step of ubiquitin conjugation by transferring ubiquitin from ubiquitin-
conjugating enzymes (E2s) to substrates. In humans, over 600 E3s contribute to 
determining the fates of thousands of substrates; hence E3s are tightly regulated to 
ensure accurate substrate ubiquitylation. Recent findings illustrate how E3s are self-
regulated and how they coordinate with E2s and substrates to meticulously conjugate 
ubiquitin.  
 
 
  
E3s are a large family of enzymes that catalyze the covalent attachment of a small 
protein modifier, ubiquitin, to a plethora of substrates in eukaryotic cells. 
Ubiquitylation (also known as ubiquitination) plays a fundamental role in nearly all 
aspects of eukaryotic cellular processes. By marking substrates with ubiquitin, E3s 
bestow substrates with new protein-protein interaction platforms that alter substrate 
activity, localization and/or interactions to elicit distinct biological signals. 
 
Ubiquitylation is achieved by the sequential actions of ubiquitin-activating enzyme 
(E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3)1-3 (Figure 1a). 
E1 uses Mg2+-ATP to form a covalent thioester between its catalytic cysteine and the 
di-glycine motif at the C-terminus of ubiquitin. E1 then transfers ubiquitin via the di-
glycine motif to E2’s catalytic cysteine to form an E2~ubiquitin thioester complex (~ 
indicates a thioester bond). E3s then bind E2~ubiquitin and substrate to facilitate 
formation of an isopeptide bond between the C-terminal carboxyl of ubiquitin and the 
ε-amino group of a substrate lysine sidechain or free N-terminal amino group. 
Successive rounds of E3-catalyzed reactions can produce substrates with 
polyubiquitin chains linked via one of ubiquitin’s seven lysine residues (Lys6, Lys11, 
Lys27, Lys29, Lys33, Lys48 and Lys63) or ubiquitin’s N-terminal methionine4 
(Figure 1b). Recognition of different ubiquitylation patterns by effectors harboring a 
ubiquitin-binding domain (UBD) elicits distinct downstream signals. For example, 
Lys48-linked polyubiquitin targets substrate to the 26S proteasome for degradation5, 6; 
Lys63-linked polyubiquitin directs substrate to the endocytic pathway7 and regulates 
kinase activation in the NFκB pathway8, and monoubiquitin plays a role in DNA 
repair9, 10 and chromatin remodeling11. 
 
In the human genome, there are two E1s, approximately 38 E2s and over 600 E3s12-14. 
Within this cascade, E3s play a pivotal role in selecting substrates and E2~ubiquitin 
to coordinate conjugation of specific ubiquitin linkages onto substrate. In this review, 
we focus on the three classes of E3s identified to date: RING (Really Interesting New 
Gene), HECT (Homologous to E6AP C-Terminus) and RBR (RING-between-RING). 
We discuss recent structural insights into the mechanisms by which E3s recruit 
E2~ubiquitin, how they prime and position ubiquitin and the substrate lysine for 
transfer, and how they extend ubiquitin chains to achieve polyubiquitylation. 
Moreover, we discuss structural details of emerging themes in E3 regulation, 
including autoinhibition.  
 
General E3 features 
All E3s harbor an E2~ubiquitin binding domain and are classified on the basis of the 
structure of this domain and their ubiquitin transfer mechanism. RING E3s catalyze 
the direct transfer of ubiquitin from E2~ubiquitin to substrate. In contrast, HECT and 
RBR E3s contain a catalytic cysteine that first receives ubiquitin from E2~ubiquitin to 
form an E3~ubiquitin thioester intermediate and subsequently transfers this ubiquitin 
to substrate (Figure 2). How E3s target substrates varies. Some contain one or several 
protein-protein interaction domains to which substrate can bind directly or indirectly 
via an interacting partner, or both. For example, the E3 ligase CBL downregulates 
EGFR signaling by ubiquitylating and targeting the receptor for lysosomal 
degradation; CBL harbors a substrate-binding domain that recognizes phosphorylated 
EGFR as well as a domain that binds the EGFR-interacting protein GRB2, which 
facilitates indirect ubiquitylation15, 16. Some E3s contain domains that bind non-protein 
molecules to mediate substrate binding and ubiquitylation. In the ER-associated 
degradation system, the E3 Cullin-RING ligase (CRL) CRLFBS1 uses a sugar-binding 
domain to recruit and ubiquitylate N-linked glycoproteins17. Other E3s lack specificity 
in their substrate selection but instead contain a domain or binding motif that recruits 
them to sites within the cell where they then ubiquitylate any accessible target. For 
example, during the repair of DNA lesions induced by ultraviolet light, the E3 
CRLDDB binds directly to pyrimidine dimer photolesions and ubiquitylates DNA-
bound XPC and DDB2 to initiate the nucleotide excision repair pathway18-20. For 
many E3s, the substrate targeting mechanism is unknown. Here we focus on how E3s 
catalyze ubiquitin transfer.   
 
RING E3s. Bioinformatic analyses predict there are around 600 RING E3s in 
humans, making it the largest of the three E3 classes14 (Supplementary Table 1). 
RING E3s are characterized by the presence of a RING domain (Figure 2a–e), which 
is the minimal component required to recruit E2~ubiquitin and stimulate ubiquitin 
transfer21. Structurally, RING domains are characterized by two zinc ions coordinated 
by cysteines and histidines arranged in a cross-braced configuration (Figure 2a–d). 
Some RING domains are active as monomers like in CBL22 (Figure 2a), CNOT423 and 
RNF3824, whereas others are active as oligomers. For example, cIAP225 (Figure 2b), 
TRAF626 and RNF427 are only active when homodimerized via their RING domains. 
Some RING domains, like the ones in BARD1, BMI1 and MDMX lack ligase activity 
but become functional upon heterodimerization with a RING domain-containing 
partner (BRCA1, RNF2 and MDM2, respectively28-32; Figure 2c). The TRIM family 
of RING E3s use their RING domains and coiled coil regions to assemble 
homodimers, heterodimers and oligomers33. Some RING E3s like CRLs and anaphase 
promoting complex/cyclosome (APC/C) are large multi-subunit complexes. CRLs 
comprise a RING E3 (RBX1 or RBX2), a cullin protein (CUL1, CUL2, CUL3, 
CUL4A/4B, CUL5 or CUL7) and a protein substrate-receptor34, 35. The cullin protein 
acts as scaffold that joins the RING domain and substrate-receptor (Figure 2d). There 
are approximately 300 different substrate-receptors in humans, making CRLs 
versatile at ubiquitylating a number of substrates. APC/C is a 1.2 MDa complex 
consisting of a 14-subunit core complex including the RING E3 APC11, the cullin-
like subunit APC2 and a coactivator protein (CDC20 or CDH1)36. U-box proteins are 
also classified as RING E3 ligases: they use the same ubiquitin transfer mechanism 
and resemble the RING domain in structure but lack zinc ions37. There are 8 U-box 
E3s in humans14 and like the RING E3s, some function as monomers like UBE4B38 
while others like PRP1939 and CHIP40 require dimerization for activity 
(Supplementary Table 1).  
 
HECT E3s. There are 28 HECT E3s in humans41. In general, they comprise an N-
terminal substrate-binding domain and a C-terminal HECT domain of approximately 
350 amino acids containing the catalytic components for ubiquitin transfer. HECT 
E3s are subdivided into three groups based on their N-terminal protein-protein 
interaction domains: the NEDD4 family with WW domains that bind PY motifs in 
substrates, the HERC family with regulator of chromosome condensation 1-like 
domains and HECTs with other protein-protein interaction domains41 (Supplementary 
Table 1). HECT domains contain two lobes connected by a flexible hinge loop 
(Figure 2f). The N-terminal lobe binds E2~ubiquitin and the C-terminal lobe contains 
the catalytic cysteine42 (Figure 2g). The flexible hinge enables the lobes to rotate and 
support ubiquitin transfer43. 
 
RBR E3s. In humans, there are 14 RBR E3s including PARKIN, HHARI, and HOIP, 
all of which possess a RING1-IBR-RING2 motif (Figure 2h and Supplementary Table 
1) as well as other domains14, 44, 45. Early studies showed that the RING1-IBR-RING2 
motif was essential for E2 binding and ligase activity but the mechanism remained 
elusive and was thought to resemble that of RING E3s46-49. However, in 2011, a 
conserved catalytic cysteine residue in the RING2 domain of HHARI and PARKIN 
was identified and found to form a thioester intermediate with ubiquitin’s C-terminus 
in a HECT E3-like manner50. This redefined the RBR E3 mechanism as a hybrid of 
RING and HECT E3 ligases, where the RING1 domain recruits E2~ubiquitin and 
transfers ubiquitin onto the catalytic cysteine of the RING2 domain prior to its 
conjugation to a substrate (Figure 2i).  
 
Structural basis of RING E3 activity  
E2s contain a highly conserved core domain of about 150 residues including a 
catalytic cysteine residue that forms a covalent thioester bond with the C-terminus of 
ubiquitin to generate E2~ubiquitin13. In the absence of E3, ubiquitin transfer from 
E2~ubiquitin to an amine can occur but the process is inefficient. Addition of a RING 
E3 massively stimulates this process24, 50-53 but until recently the mechanism 
underlying this stimulation was not well understood. In 2000, the first crystal 
structure of a RING E3-E2 complex, CBL-UBE2L3, showed that CBL’s RING 
domain binds the L1 and L2 loops and N-terminal α1 of UBE2L3. In this E3-E2 
conformation, E2’s active site is distal from the RING domain, precluding direct 
participation of the RING domain in catalysis22. Although CBL is not reactive with 
UBE2L3, these E3-E2 interactions are conserved in subsequently determined 
structures of reactive RING E3-E2 pairs. Ensuing studies suggested that RING E3 
binding might induce allosteric changes in E2’s active site51, 54, but details remained 
elusive. In 2012, the crystal structures of RNF455 and BIRC756 bound to E2–ubiquitin 
(en dash denotes a covalent interaction used to mimic E2~ubiquitin) and NMR 
analyses of E4B in complex with the E2 UBE2D3–ubiquitin57 revealed the catalytic 
mechanism of RING E3-mediated ubiquitin transfer (Figure 3).  
 
Priming ubiquitin for transfer  
NMR and SAXS analyses showed that in the absence of a RING E3, 
UBE2D3~ubiquitin is highly dynamic and prefers to adopt open conformations where 
there is little or no interaction between the E2 and ubiquitin; in contrast, analyses of 
the E2 UBE2N~ubiquitin conjugate showed it more frequently adopts closed 
conformations but is still dynamic58. For the UBE2D family of E2s, addition of a 
RING E3 shifts the equilibrium toward closed conformations in which ubiquitin is 
proximal to the RING domain and more reactive toward transfer56, 57, 59, 60 (Figure 3a).  
When ubiquitin is optimally positioned or “primed” for transfer, the RING domain 
binds both the E2 and the Ile36 surface of ubiquitin, and the Ile44 surface of ubiquitin 
contacts α2 of the E2 (Figure 3b). The C-terminal tail of ubiquitin (residues 71-76) is 
braced in a conformation favorable for catalysis in which the incoming lysine can be 
deprotonated and the thioester oriented for attack. The acquisition of a primed 
ubiquitin conformation in the presence of a RING E3 appears to be conserved across 
different E2s and RING E3s and has been corroborated by various crystal structures24, 
55, 56, 61-65 and biochemical studies53, 66. Collectively, these works show that several 
E2~ubiquitin conjugates are not reactive for transfer of ubiquitin onto a lysine 
because they adopt various inactive conformations; interactions with RING E3s favor 
the acquisition of a closed E2~ubiquitin conformation where ubiquitin is primed for 
transfer. 
 
Key interactions in the primed conformation  
The sidechain of an arginine from the RING E3 forms hydrogen bonds with both the 
E2 and ubiquitin, thereby functioning as a “linchpin”57 within the RING E3-UBE2D-
ubiquitin interface to stabilize the primed ubiquitin conformation (Figure 3c). Direct 
interactions between this linchpin Arg and the carbonyl of Arg72 of ubiquitin 
contribute to constraining the C-terminal tail of ubiquitin in an activated conformation 
along E2’s active site cleft. Most E2s contain an HPN motif within their active sites 
that is critical for catalysis. The asparagine from this motif stabilizes the loop 
comprising residues 114-117 from the E2 UBE2D255, 67 (Figure 3d). This loop helps 
stabilize the tail of ubiquitin and, as observed in the SUMO E268, contains an aspartate 
that reportedly reduces the pKa of the incoming substrate lysine to facilitate 
catalysis55.  
 
While the RING domain alone primes E2~ubiquitin57, the presence of various 
additional ubiquitin-binding components in some RING E3s helps stabilize 
E2~ubiquitin in the primed conformation and enhance activity (Figure 3e)56, 61. In 
CBL-B, the phosphate moiety of phospho-Tyr363 forms a hydrogen bond with 
ubiquitin’s Thr9 sidechain61 and in RNF38, loops adjacent to RNF38’s RING domain 
contact the Thr9-containing surface of ubiquitin24. In the monomeric RING E3 
ARK2C, ubiquitin transfer requires binding of a second molecule of ubiquitin to the 
RING domain opposite the E2-binding surface; modeling and biochemical data 
suggest that this ubiquitin directly contacts and stabilizes the E2-conjugated ubiquitin 
for transfer69. For the dimeric RING E3s RNF4 and BIRC7, the RING domain of one 
subunit and the C-terminal tail of the second RING subunit interact with the Gly35-
containing surface of ubiquitin55, 56. A conserved aromatic residue in the C-terminal 
tail from both of these dimers is critical for this interaction (Figure 3e). In contrast, 
the RING E3 TRIM25 has a different dimer interface and lacks a conserved aromatic 
tail. In the TRIM25-UBE2D1–ubiquitin complex structure, the N-terminal helix from 
one subunit and C-terminal helix from the second subunit make hydrophilic 
interactions with the Gly35-containing surface of ubiquitin65. For many RING E3s, 
these additional components are distinct features that require additional structural and 
biochemical studies to fully characterize their roles in RING E3-mediated 
ubiquitylation. 
 
Additional E2-E3 interactions  
Several RING E3s harbor an additional domain that binds to the “backside” surface of 
the E2 opposite the active site (Figure 3f). For example, the G2BR domain of gp78 
allows such ‘backside’ interactions with the E2 UBE2G270. Similarly, U7BR of 
Cue1p binds UBC771, R6BD of RAD18 binds RAD672 and U5BR of AO7 binds 
UBE2D273. These various E3 domains that facilitate ‘backside’ binding of E2s all 
enhance RING E3-E2 affinity but affect activity disparately. G2BR stimulates 
ubiquitylation by inducing conformational changes at the RING-UBE2G2 interface 
that enhance UBE2G2~ubiquitin binding70. Moreover, RING domain binding reduces 
G2BR-UBE2G2 affinity, thereby enabling release of UBE2G2 and promoting 
processive ubiquitylation74. U7BR binding not only enhances RING E3-E2 affinity, 
but also increases the accessibility of UBC7’s active site to E1 and ubiquitin’s K48 to 
respectively facilitate recharging and substrate ubiquitylation71. In some E2s like 
RAD6 and the UBE2D family, noncovalent backside binding of ubiquitin promotes 
processive polyubiquitin chain formation72, 75-77 (Figure 3f). For UBE2D2, noncovalent 
ubiquitin binding induces allosteric changes in the E2 that increase the affinity of 
RING E3s for E2~ubiquitin and the catalytic efficiency of ubiquitylation leading to 
enhanced initial ubiquitin transfer and subsequent polyubiquitin chain formation24. 
U5BR enhances AO7’s affinity for UBE2D2 but blocks noncovalent ubiquitin 
binding, leading to decreased ubiquitylation activity73. Similarly, R6BD binding to 
RAD6 competes against noncovalent ubiquitin binding and limits RAD18 catalysis to 
monoubiquitylation72. 
  
Transfer of ubiquitin onto substrate 
To transfer ubiquitin to substrate, RING E3s juxtapose a substrate lysine and 
E2~ubiquitin thioester. How different RING E3s accomplish this varies, but in each 
case accessibility of the substrate lysine governs its capacity for ubiquitylation. This is 
discussed in the substrate ubiquitylation outcomes section. 
   
Structural basis of HECT E3 activity 
HECT E3s are characterized by an N-lobe that binds E2 connected by a hinge to a C-
lobe containing the catalytic cysteine. The L1 and L2 loops and N-terminal α1 of E2 
interact with an 80-residue subdomain in the HECT E3 N-lobe42, 78, 79. Following 
binding of E2~ubiquitin, ubiquitin is transferred from the E2 to the catalytic cysteine 
on the C-lobe of the HECT domain in a transthiolation reaction. The primed 
HECT~ubiquitin is then subsequently juxtaposed with and transferred to a substrate 
lysine. 
 
Mechanism of transthiolation  
In structures of the HECT E3s E6AP, WWP1 and SMURF2, the position of the C-
lobe relative to the N-lobe varies, demonstrating that the hinge between the two lobes 
is flexible42, 43, 80 (Figure 4a–c). Early structures and models of HECT E3-E2 
complexes revealed a large distance between the E2 and HECT E3 catalytic cysteines, 
suggesting conformational changes are required for the E2-E3 transthiolation reaction 
(Figure 4c). Subsequently, the crystal structure of NEDD4L bound to UBE2D2–
ubiquitin showed that rotation about the hinge allowed the C-lobe to bind ubiquitin 
and position its catalytic cysteine adjacent to the UBE2D2–ubiquitin linkage to 
facilitate transthiolation78 (Figure 4d). In the current NEDD4L transthiolation model, 
the N-lobe initially recruits E2~ubiquitin, and upon rotation about the hinge, the C-
lobe binds ubiquitin and juxtaposes both catalytic cysteines to promote formation of 
the HECT E3~ubiquitin intermediate. This mechanism is likely shared among 
NEDD4 family HECT E3s since residues contributing to hydrophobic interactions 
with Ile36 and surrounding residues of ubiquitin are conserved. These residues are not 
conserved in other HECT E3s; hence, further studies are required to elucidate how 
these other HECT E3s engage ubiquitin for transthiolation. 
 
Priming ubiquitin for transfer 
The step immediately following the transthiolation reaction was captured in a crystal 
structure of a NEDD4–ubiquitin complex81 (Figure 4e). The interactions between 
ubiquitin and the C-lobe are identical to those observed in the structure of NEDD4L-
UBE2D2–ubiquitin complex prior to transfer. Notably, ubiquitin’s C-terminal tail is 
positioned in an extended conformation by a hydrogen bond network involving 
backbone carbonyl oxygens and amides from the C-lobe. Constraining the position of 
ubiquitin’s C-terminus appears to be a common thioester-activating mechanism for 
RING and HECT E3s in which E3-E2~ubiquitin structural data is available.  
 
Transfer of ubiquitin to substrate 
In the subsequent step, HECT E3~ubiquitin juxtaposes the E3~ubiquitin thioester and 
substrate lysine. This process was recently captured in the crystal structure of Rsp5–
ubiquitin-Sna3 complex where a three-way chemical cross-linker was used to link 
Rsp5’s catalytic cysteine, ubiquitin’s C-terminus and a lysine sidechain of Sna3 
substrate peptide82 (Figure 4f). The C-lobe undergoes a 130° rotation about the 
flexible linker relative to its conformation in the NEDD4L-UBE2D2–ubiquitin and 
NEDD4–ubiquitin complexes (Figure 4e–g). Almost half of the N-lobe contacts the 
C-lobe to stabilize this conformation. Crucially, Phe806 from the C-lobe of Rsp5, also 
known as the “-4 phenylalanine”, sits in an N-lobe pocket containing Phe505 and 
Leu506. This -4 phenylalanine is conserved in all types of HECT E3s and is required 
for substrate ubiquitylation and polyubiquitin chain formation but not 
HECT~ubiquitin formation83, 84. Interestingly, mutations of this Phe to Leu (Rsp5 
F806L) can be rescued by a complementary substitution of Leu506 to Trp (L506W) 
or to Phe (L506F), suggesting that Phe806 anchors the two HECT domain lobes in an 
orientation suitable for substrate ubiquitylation82. It is noteworthy that the amino acid 
composition of this N-lobe pocket is conserved in the NEDD4 E3s, but diverges in 
other HECT E3s. Furthermore the extreme C-terminus of HECT E3s has been shown 
to be important for ligation81, 83 but this region is disordered in all HECT E3 
structures. Future studies are required to investigate these differences in the HECT E3 
subfamilies and the role of the C-terminus in ligation.  
 
The Rsp5–ubiquitin-Sna3 structure does not capture a substrate lysine poised for 
ligation but modeling and mutational analyses suggest that residues surrounding 
Rsp5’s catalytic cysteine contribute to Sna3 ubiquitylation82. The Rsp5~ubiquitin 
thioester sits adjacent to an N-lobe loop (residues 490-495) harboring Asp495 (Figure 
4f), an essential residue for ligation82. Unfortunately this loop is disordered in the 
Rsp5–ubiquitin-Sna3 structure. Modeling based on other HECT E3 structures, in 
which the loop is ordered and contains a structurally conserved aspartate, suggests 
that this loop may function in positioning the C-terminus of ubiquitin. Additionally, in 
the model Asp495 juxtaposes with the E3~ubiquitin thioester, where it can potentially 
guide a substrate lysine into the active site or contribute to substrate lysine 
deprotonation82. Future studies are required to determine how the aspartate-containing 
N-lobe loop and active site residues participate in substrate ubiquitylation and chain 
elongation in HECT E3s.  
 
The NEDD4-family HECT E3s harbor a noncovalent ubiquitin-binding site on the N-
lobe80, 81, 85-87 (Figure 4e). Disruption of this interaction impairs polyubiquitin chain 
elongation but not E2-E3 transthiolation or the conjugation of the first ubiquitin to 
substrate86, 87. This noncovalent ubiquitin is distal from the E3~ubiquitin thioester in 
all available structures, suggesting it does not serve as the acceptor ubiquitin. 
Biochemical data suggest this site might bind ubiquitin-modified substrate to promote 
processive polyubiquitin chain formation87. The exact mechanism remains to be 
determined. 
 
Structural basis of RBR E3 activity  
Structures of PARKIN, HHARI and HOIP show that RING1, IBR and RING2 
domains from different RBR E3s share a common structural fold88-97. RING1 adopts a 
cross-braced Zn2+-coordination configuration found in typical RING domains whereas 
IBR and RING2 each have two zinc ions coordinated in a linear fashion. RING1 
recruits E2~ubiquitin and transfers ubiquitin to the catalytic cysteine on RING2 to 
form a RING2~ubiquitin intermediate; ubiquitin is subsequently transferred to 
substrate. The structures of PARKIN, HHARI and HOIP show distinct RING1-IBR-
RING2 arrangements (Figure 5). In the structure of the RBR region from HOIP bound 
to E2–ubiquitin, the RBR adopts an active conformation92. In the full-length structures 
of PARKIN and HHARI, both adopt autoinhibited conformations where the 
arrangement of the RBR motif is determined by other domains unique to each RBR 
E393-97. In PARKIN, a RING0 domain is sandwiched between RING1 and RING2 
with IBR placed adjacent to RING1; in HHARI, a C-terminal Ariadne domain is 
stacked between IBR and RING2 and RING1 is secluded by an ubiquitin associated 
(UBA) domain at the opposite end of RING2 (Figure 5a,b).  
 
Formation of RING2~ubiquitin  
Given the structural similarity between the RING1 and canonical RING domains, 
modeling of the RING1 domain from PARKIN and HHARI onto RING E3-
E2~ubiquitin complexes reveals that all RING1 domains harbor similar hydrophobic 
cores that interact with hydrophobic residues in the L1 and L2 loops of E2 (Figure 
5c,d). These hydrophobic interactions were observed in the structure of HOIP’s RBR 
bound to UBE2D2–ubiquitin92. However, RING1 domains lack the linchpin arginine 
that promotes the closed, primed E2~ubiquitin conformation required for ubiquitin 
transfer to a lysine. In contrast to RING E3s, RBR E3s function with UBE2L3, an 
intrinsically cysteine-reactive E250. Without RING2 or with catalytically dead RING2, 
HHARI cannot promote transfer of UBE2L3~ubiquitin50, 93. Taken together, these 
works suggest that the RING1 domain does not activate E2~ubiquitin like a canonical 
RING E3; instead, data indicate the RBR E3s resemble HECT E3s in function. 
Depending on the class of E3, either the N-lobe or RING1 recruit E2~ubiquitin and 
juxtaposition with the C-lobe or RING2 promotes formation of E3~ubiquitin.  
 
The recent HOIP-UBE2D2-ubiquitin complex structure reveals how these catalytic 
cysteines are juxtaposed92. Multiple interactions with RING1, RING2, IBR and 
regions between these components stabilize UBE2D2–ubiquitin in an open 
conformation92 (Figure 5e). The Ile44 surface of ubiquitin contacts a helix between 
IBR and RING2, thereby enabling RING2 to bind UBE2D2 and stabilize ubiquitin’s 
C-terminal tail in an extended conformation such that the UBE2D2 and RING2 
catalytic cysteines are juxtaposed. The RING1-IBR module adopts an elongated 
conformation where RING1 and IBR are connected by two extension helices, hE1 and 
hE2. RING1 binds UBE2D2 and hE2-IBR binds the surface of ubiquitin containing 
Lys11 and Glu34. There is an additional ubiquitin-binding site on the RING1-IBR 
region opposite the UBE2D2–ubiquitin-binding site. This ubiquitin (hereby referred 
to as ubiquitinAllo) functions as an allosteric activator by enhancing 
UBE2D2~ubiquitin binding and RING2~ubiquitin formation. Like HOIP, PARKIN 
and HHARI both have similar RING1-IBR-RING2 module and two helices between 
RING1 and the IBR region (Figure 5a,b,e), suggesting they share a similar 
mechanism of E2~ubiquitin binding. How PARKIN and HHARI undergo 
conformational changes to juxtapose E2 and RING2’s cysteines and how other 
domains influence this transition remain to be determined. 
 Transfer of ubiquitin to substrate  
Our current understanding of how RBR E3s recognize their substrates is limited to 
HOIP-mediated linear ubiquitin chain formation. This process is facilitated by the 
presence of a linear ubiquitin chain determining domain (LDD) in HOIP that binds 
and orients the acceptor ubiquitin98, 99. In the crystal structure of HOIP RING2 and 
LDD bound to acceptor ubiquitin, the C-terminus of a second ubiquitin molecule is 
oriented with its carboxylate positioned next to the active site cysteine of RING2, 
thereby mimicking a HOIP~ubiquitin intermediate (Figure 5f). Thus the structure 
captures both donor and acceptor ubiquitin in conformations poised for linear 
ubiquitin chain synthesis88. The C-terminal tail of the donor ubiquitin lies along a 
hydrophobic groove surrounding the catalytic cysteine in the core of the RING2 
domain; interactions with this groove and a β-hairpin from the RING2 domain 
stabilize the tail in an extended conformation (Figure 5f). The RING2 domains from 
PARKIN and HHARI also contain hydrophobic grooves proximal to the catalytic 
cysteine, suggesting they may use an E3~ubiquitin-binding mode similar to HOIP 
when mediating ubiquitin transfer to substrate. However, they lack the β-hairpin 
present in HOIP and have different domains outside of the RBR motif implicated in 
substrate binding; hence, further studies are required to elucidate how PARKIN and 
HHARI juxtapose RING2~ubiquitin and substrate.  
 
HOIP RING2-ubiquitin and HOIP-UBE2D2–ubiquitin complexes have identical 
donor ubiquitin-binding modes, indicating that the ubiquitin-binding mode is 
maintained throughout E2-E3 ubiquitin transfer and substrate ubiquitylation92. The 
acceptor ubiquitin-RING2 interaction overlaps with the UBE2D2-RING2 interface in 
the HOIP-UBE2D2–ubiquitin complex, suggesting acceptor ubiquitin and 
E2~ubiquitin binding are mutually exclusive. Thus, for successive rounds of substrate 
ubiquitylation, acceptor ubiquitin must be released from RING2 after transfer to allow 
additional rounds of E2~ubiquitin recruitment and RING2~ubiquitin formation 
(Figure 5g). How such arrangements promote ubiquitin chain elongation is unclear.  
 
Substrate ubiquitylation outcomes 
Once ubiquitin is primed, an E3 positions a lysine sidechain from a substrate next to 
the E2~ubiquitin or E3~ubiquitin thioester for ligation. Subsequently, the E3 may 
release the substrate, resulting in monoubiquitylation. Alternatively, the E3 may 
catalyze consecutive ubiquitin transfers in which multiple lysine sites on a substrate 
are modified with a single ubiquitin resulting in multi-monoubiquitylation or 
polyubiquitin chains are formed with a selective linkage at a single or multiple lysine 
sites. Polyubiquitylation involves two events: chain initiation where ubiquitin is 
transferred to a lysine on the substrate and chain elongation where ubiquitin is 
transferred to a lysine on a ubiquitin moiety from ubiquitylated substrate. For some 
RING E3s, a single E2 is reportedly responsible for both events75 while in others one 
E2 monoubiquitylates substrate and a second E2 performs chain elongation100-102.  
 
To mediate this array of ubiquitylation outcomes, diverse mechanisms are required. 
For monoubiquitinylation, E3s require a method to prioritize or isolate a single lysine 
on a substrate. On the other hand, for multi-monoubiquitylation and chain elongation, 
E3s must be flexible to bridge the varying distances between the E3~ubiquitin or 
E2~ubiquitin thioester and the target lysine. Flexibility is also required in E3s that 
interact with multiple substrates via discrete domains. Currently, no consensus 
ubiquitylation motif has been determined. For RING E3s, it is widely accepted that 
the E2 specifies the ubiquitin chain type or lysine site that is modified; however, it is 
the RING E3 that regulates the accessibility of substrate lysines to the E2~ubiquitin 
thioester. The emerging theme from recent structural studies on E2/E2~ubiquitin-
RING E3-substrate and HECT E3~ubiquitin-substrate complexes illustrates that 
spatial arrangements and surface complementarity prioritize lysine site(s) for 
ubiquitylation64, 82, 103-105. Because E2~ubiquitin-E3-substrate and E3~ubiquitin-
substrate complexes use different mechanisms to bind substrate, how they specify 
substrate lysine site(s) for ubiquitylation will vary. Here we discuss some examples.  
 
Lys125 prioritization on Sna3 by the HECT E3 Rsp5  
The HECT E3 Rsp5 mediates ubiquitylation and sorting of most multivesicular body 
cargo proteins in yeast, including Sna3106-109. Rsp5 interacts directly with Sna3 to 
ubiquitinylate Lys125: the WW3 domain of Rsp5 binds to the PY motif in Sna3, 
which is separated from Lys125 by a 15-residue linker82. This linker is sufficient to 
bridge the gap between Rsp5’s catalytic cysteine and Sna3’s PY motif in the Rsp5-
ubiquitin-Sna3 complex (Figure 6a). Deletion of the linker to less than 10 residues 
strongly reduces ubiquitylation of Sna3, suggesting that Rsp5 domains do not rotate 
freely during ligation. The distance between Rsp5’s active site and Sna3’s PY motif 
seemingly selects the lysine ubiquitylation site82.  
 
Site-specific monoubiquitylation of H2A by RNF2-BMI1  
Monoubiquitinylation of Lys119 in H2A by the heterodimeric RING E3 RNF2-BMI1 
complex is important for Polycomb-group proteins to mediate gene-silencing110. In the 
crystal structure of RNF2-BMI1-UBE2D3 complex bound to the nucleosome core 
particle (NCP)103 (Figure 6b), the RING domain is anchored onto the NCP through 
interactions with all four histones and UBE2D3 forms a complementary surface with 
the nucleosomal DNA and H2A’s C-terminus, thereby restricting RING mobility and 
the orientation of the E2. Usually, substrate lysine modification by RING E3s with the 
UBE2D family of E2s is promiscuous, but in this configuration, the accessibility of 
the catalytic cysteine from the E2 is limited to a specific substrate lysine. For RING 
E3s to build ubiquitin chains, either the RING-E2 module or the ubiquitylated 
segment of substrate must rotate. In the RNF2-BMI1-UBE2D3-NCP complex, 
UBE2D3, nucleosomal DNA and histones H3 and H4 surround H2A’s C-terminus, 
thereby restricting movement of the substrate. Because both the RING-E2 and 
substrate elements are constrained in the RNF2-BMI1-UBE2D3-NCP complex, only 
monoubiquitylation occurs.  
 
Lysine selection with a mobile RING domain 
In E3s such as CBL61, 111, 112, CRL64, 113-115 and APC/C104, 105, 116 (Figure 6c), a flexible 
linker between the RING and other domains allows the E2~ubiquitin-bound RING 
domain to sample multiple conformations. APC/C facilitates all known degradation 
events controlling mitotic exit. More than 50 substrates have been identified in 
genome-wide studies117, yet this E3 tightly regulates lysine selectivity and chain 
elongation. How does APC/C select preferred lysine sites when flexible? For APC/C, 
CDH1 binding induces a conformational change in the APC2 and APC11 subunits to 
stimulate activity116. This enables bipartite interactions with UBE2C where the RING 
domain APC11 binds UBE2C via canonical E2-RING interactions and the winged-
helix B domain of APC2 interacts with UBE2C’s backside105 (Figure 6c). This 
bipartite UBE2C binding restricts the orientation of the APC11-UBE2C module such 
that UBE2C’s active site prioritizes lysines residing ten residues beyond CDH1’s D-
box and KEN-box substrate-binding motifs104, 105.  
 
Positioning of ubiquitin for chain elongation  
To build a specific ubiquitin linkage, a particular lysine from a ubiquitin molecule 
ligated to substrate must be poised for ligation with the donor ubiquitin. Ubiquitin 
chain linkage specificity depends on the E2 pairing for RING E3s and the E3 itself for 
HECT and RBR E3s4, 13, 88,118. Current structural understanding of acceptor ubiquitin 
positioning for generating specific ubiquitin–ubiquitin linkages is limited to UBE2N-
UBE2V2-catalyzed Lys63-linked ubiquitin chains, in which UBE2V2 determines 
chain specificity,62, 119 and HOIP-catalyzed linear ubiquitin chains, in which the E3 
determines chain specificity. Both UBE2V2 and HOIP harbor a ubiquitin-binding 
domain that binds acceptor ubiquitin and orients Lys63 (in the case of UBE2V2) or 
Met1 (in the case of HOIP) toward the catalytic cysteine for ligation. However, it 
remains unclear how E3s position ubiquitylated substrate for chain elongation. 
 
Recent studies of APC/C reveal a novel mechanism whereby acceptor ubiquitin at the 
tip of a growing substrate ubiquitin chain is tracked and E3 and E2 function together 
to determine chain specificity120, 121. APC/C uses a coactivator, CDC20 or CDH1, to 
recognize and bind substrates containing D- or KEN-box motifs and initially recruits 
UBE2C~ubiquitin via the canonical APC11 RING-E2 binding surface to transfer 
ubiquitin to substrate122 (Figure 6c). Subsequently it recruits UBE2S~ubiquitin via a 
distinct APC2 surface that binds the C-terminal LRRL motif of UBE2S116, 123, 124 and 
guides UBE2S-mediated Lys11-linked ubiquitin chain elongation on substrate120, 121 
(Figure 6c). APC/C stabilizes UBE2S’s core domain and binds the acceptor ubiquitin 
via a distinct hydrophobic patch on the APC11 RING domain opposite the UBE2C-
binding surface. These abilities massively enhance the catalytic efficiency of the 
APC/C-UBE2S complex, presumably by enabling APC/C to juxtapose UBE2S’s 
active site and acceptor ubiquitin lysine on substrate to promote Lys11-linked 
polyubiquitylation.  
 
These examples illustrate a common mechanism whereby an E2-E3 or E3 catalytic 
module is secured in a conformation that juxtaposes the ubiquitin thioester with select 
substrate lysine site(s) for ligation and chain elongation. For each example, structural 
features of the E3, E2 and substrate determine lysine selectivity and subsequent 
ubiquitin chain formation. Future studies on other E3-substrate systems will reveal 
how different structural features regulate ubiquitylation. 
  
Regulation of E3 activity 
Over the last 15 years, numerous mechanisms including post-translational 
modifications of E2, E3 and substrate as well as binding of protein partners and small 
molecules, exemplified how E3s are regulated throughout their catalytic cycle21. 
Recent studies demonstrated that all three classes of E3s are also regulated by 
autoinhibitory mechanisms involving catalytically incompetent E3 conformations in 
which E2~ubiquitin cannot be recruited or E3 flexibility is limited. In every study, 
domains other than those that define each class of E3 are involved; hence, how 
autoinhibition and activation are mediated depends on the E3. Here we describe an 
example from each class of E3s. 
 
cIAP1 autoinhibition and activation 
Cellular inhibitor of apoptosis 1 (cIAP1 or BIRC2) is a dimeric RING E3 that plays a 
central role in the NF-κB signaling cascade and programmed cell death125. cIAP1 
contains three N-terminal baculoviral IAP repeat (BIR1-3) domains followed by a 
UBA domain, a caspase activation and recruitment domain (CARD) and a RING 
domain. In the crystal structure of cIAP1 lacking the BIR1 and 2 domains, cIAP1 is in 
an inactive conformation where the RING domain is sequestered and the protein is a 
monomer (Figure 7a). RING sequestration prevents dimerization, thereby impairing 
E2~ubiquitin recruitment126, 127. SAXS analyses showed that cIAP1 is dynamic and 
undergoes global conformational changes whereby the BIR3 peptide-binding groove 
is exposed128. Binding of second mitochondrial activator of caspases (SMAC) peptide 
or a SMAC peptide mimetic to the BIR3 domain disrupts the autoinhibited 
conformation, thereby activating ligase activity by enabling RING domain 
dimerization and subsequent E2~ubiquitin recruitment126, 129 (Figure 7a). 
 
SMURF2 autoinhibition and activation  
The NEDD4 family of HECT E3s including SMURF1, SMURF2, ITCH, NEDD4_1 
and NEDD4_2 share a similar domain architecture containing an N-terminal C2 
domain followed by two to four WW domains and a C-terminal HECT domain and 
are regulated by autoinhibition130-135. SMURF2 is better characterized and is 
autoinhibited by interactions between the C2 and HECT domains135. NMR analyses 
reveal that interactions between the C2 domain and the N-lobe of the HECT domain 
restrict the C-lobe to an inactive conformation in which transthiolation is 
unsupported135, 136 (Figure 7b). Moreover, this interaction partially buries the N-lobe 
noncovalent ubiquitin-binding surface essential for E3 processivity136. SMURF2 is 
activated upon binding of the adaptor protein SMAD7. Interactions between the PY 
motif of SMAD7 and SMURF2’s WW domain and SMAD7’s N-terminal domain and 
SMURF2’s HECT domain release the C2 domain135, 137 (Figure 7b). Moreover, 
SMAD7 assists E2 binding by SMURF280. 
 
Autoinhibition and activation of PARKIN  
In RBR E3s with characterized autoinhibitory mechanisms, domains outside of the 
RBR motif mediate autoinhibition93-99, 138. Of the three RBR E3s that have structural 
data available, PARKIN is a better-characterized example. PARKIN plays an 
important role in mitochondria quality control. When mitochondria are damaged, 
PINK1 accumulates on the outer mitochondrial membrane and recruits PARKIN139. 
PINK1 phosphorylates Ser65 in PARKIN’s UBL domain and ubiquitin’s Ser65 on 
mitochondrial polyubiquitin chains. Phosphorylation of PARKIN’s Ser65 enhances its 
ligation activity, which is further stimulated by phospho-Ser65 ubiquitin140. Binding 
of phospho-Ser65 ubiquitin increases the activity of unphosphorylated PARKIN and 
enhances PINK1-dependent phosphorylation of PARKIN’s Ser65118, 140-142. This 
synergistic effect establishes a feed-forward mechanism118 to ensure that PARKIN is 
activated and able to efficiently ubiquitylate mitochondrial outer membrane 
proteins143, 144 and promote mitophagy. In the autoinhibited state, there is a large gap 
between the RING1 domain and the RING2 catalytic cysteine in which E3~ubiquitin 
formation is unsupported94-97, 138, 145 (Figure 5c). Moreover, the RING0 domain binds 
the RING2 domain and masks the catalytic cysteine (Figures 5a and 7c) and an 
additional repressor element (REP) within the RBR motif and the N-terminal UBL 
domain occlude the E2~ubiquitin-binding site on the RING1 domain94-97, 145. 
Phosphorylation of PARKIN’s Ser65 releases the UBL domain from RING1 to allow 
E2~ubiquitin binding and alters the RING0/RING1 interface to improve phospho-
Ser65 ubiquitin binding97, 118, 140, 145, 146. Phospho-Ser65 ubiquitin binding to the RING1-
IBR surface opposite the E2~ubiquitin binding site induces straightening of a “bent” 
RING1-IBR helix that promotes conformational changes in the IBR-REP region, 
thereby leading to the release of the UBL domain from PARKIN146 (Figures 7c,d). 
Activated PARKIN and HOIP have similar RING1-IBR conformations, suggesting 
that straightening of the RING1-IBR linker helix may be a prerequisite for 
E2~ubiquitin binding to RBR E3s92. 
 
Conclusions and future perspectives 
Our understanding of the pivotal role E3s play in affecting cellular processes has 
grown exponentially. The capacity of E3s to mediate ubiquitin chain formation 
depends on the ability to recruit E2~ubiquitin and promote ubiquitin transfer. Spatial 
arrangements of E3-E2-substrate complexes dictate substrate ubiquitylation patterns. 
Technologies have only advanced enough in the last decade to support the preparation 
of sufficient quantities of E2~ubiquitin and E3~ubiquitin suitable for structural and 
biochemical analyses. Consequently, we have gained several insights into the 
mechanisms underlying E3-mediated ubiquitylation and regulation. However, given 
that current structural studies encompass only a fraction of all E3s, future studies are 
required to uncover the functions and mechanisms of other uncharacterized E3s. 
Chemical cross-linkers such as those used in the studies of Rsp582 and APC/C105 will 
facilitate structural studies of intermediates in E3-catalyzed reactions, allowing us to 
investigate mechanisms of E3-catalyzed substrate ubiquitylation and 
polyubiquitylation. Furthermore, recent methods for introducing site-specific 
ubiquitin modifications to substrate147-153 will be useful tools for further dissecting E3-
catalyzed polyubiquitylation. Lastly, there is a growing interest in targeting E3s with 
cancer therapeutics. A better understanding of the mechanisms of E3-catalyzed 
reactions and regulation will greatly aid the development of such E3 inhibitors. 
  
Figure legends 
Figure 1. Ubiquitin conjugation system. a | Schematic diagram of ubiquitin 
conjugation cascade. E1 catalyzes two rounds of adenylation of ubiquitin (labelled Ub 
in figure) in the presence of Mg2+ and ATP to bind two molecules of ubiquitin: one 
forms a thioester with E1’s catalytic cysteine and the other is bound non-covalently 
via its AMP-modified C-terminus to E1’s adenylation domain. E1 then binds E2 and 
transfers ubiquitin from its catalytic cysteine to E2’s catalytic cysteine to form 
E2~ubiquitin. E2~ubiquitin dissociates from E1 and E1 re-enters its catalytic cycle. 
E3 recruits E2~ubiquitin and substrate to catalyze ubiquitin transfer to substrate. 
Upon transfer, E2 disengages from E3 and E3 binds another E2~ubiquitin to catalyze 
the next round of substrate ubiquitylation. b | Substrate ubiquitylation outcomes. 
Ubiquitylated substrates interact with binding partners that harbour ubiquitin-binding 
domains, thus altering protein-protein interactions and cellular functions of substrates. 
A single molecule of ubiquitin can be attached to substrate at one 
(monoubiquitylation) or multiple (multi-monoubiquitylation) lysine sites. 
Additionally, the seven surface lysine residues (labelled as K and number in the 
protein structure) and N-terminal methionine (labelled as M1) of ubiquitin can serve 
as acceptor sites leading to the formation of polyubiquitin chains. These chains can be 
homogeneous like K48-linked and K63-linked polyubiquitin, where only one site on 
ubiquitin is modified, or branched, where two molecules of ubiquitin are attached to 
different acceptor sites on a single ubiquitin molecule. Different ubiquitin linkages 
vary in structure and therefore recruit discrete interacting partners to produce unique 
downstream signals147, 154. APC/C synthesizes branched ubiquitin chains on its 
substrate, resulting in enhanced substrate recognition and degradation by the 26S 
proteasome155. 
 Figure 2. E3 catalytic mechanisms. a–e | RING E3-catalyzed ubiquitin transfer. (a) 
Crystal structure of a monomeric RING E3 from c-CBL (PDB: 1FBV). The RING 
domain is in orange and the substrate-binding domain is in grey. (b) Crystal structure 
of a dimeric RING E3 from cIAP2 (PDB: 3EB5). One RING domain is colored 
orange and the other yellow. (c) NMR structure of BRCA1-BARD1 RING domain 
heterodimer (PDB: 1JM7). BRCA1 is colored in orange and BARD1 is in yellow. (d) 
Crystal structure of a multi-subunit RING E3 CRL. The RING domain is in orange, 
CUL1 is in blue, and the substrate receptor is in grey. (e) A schematic drawing of 
RING E3-mediated catalysis. The RING domain binds E2~ubiquitin and a substrate-
binding domain recruits substrate. Ubiquitin is transferred directly from E2 to a 
substrate lysine. f,g | HECT E3-catalyzed ubiquitin transfer. (f) Crystal structure of a 
HECT domain from NEDD4L (PDB: 3JVZ). C- and N-lobes are indicated. C-lobe’s 
catalytic cysteine is shown as a yellow sphere. (g) A schematic drawing of HECT E3 
catalysis. N-lobe of the HECT domain binds E2~ubiquitin and a substrate-binding 
domain recruits substrate. Ubiquitin is transferred from E2 to the catalytic cysteine of 
the C-lobe of the HECT domain and subsequently to a substrate lysine. h,i | RBR E3-
catalyzed ubiquitin transfer. (h) Crystal structure of an RBR domain from 
autoinhibited PARKIN (PDB: 5C23). RING1, IBR and RING2 are indicated. 
RING2’s catalytic cysteine is shown as a yellow sphere. The grey helix is a fragment 
of the repressor element. Dashed lines indicate disordered regions. This autoinhibited 
arrangement is specific to PARKIN and may not be representative of all E3s. (i) A 
schematic drawing of RBR E3 catalysis. RING1 domain binds E2~ubiquitin and 
ubiquitin is transferred from E2 to RING2’s catalytic cysteine and then to a substrate 
lysine. How RBR E3s bind substrates remain elusive. PARKIN is recruited to the 
damaged mitochondria by PINK1 and ubiquitylates proteins bound to the outer 
mitochondria membrane143, 144. HOIP contains a zinc finger motif in the RING2 
domain that binds ubiquitin as described later in Figure 4f. Zinc atoms, which 
function to stabilize domain folding, are shown as grey spheres. 
 
Figure 3. Mechanism of priming ubiquitin for transfer by RING E3s. a | RING E3 
binding induces the formation of a closed E2~ubiquitin conformation that is primed 
for catalysis. Left panel, in the absence of RING E3, ubiquitin samples various 
conformations relative to E2. Middle panel, RING E3 binding shifts the equilibrium 
toward the closed and primed E2~ubiquitin conformation. Right panel, the presence 
of an additional ubiquitin-binding component outside the RING domain further 
stabilizes the primed E2~ubiquitin conformation. Examples of the additional 
component are shown in e. E2 is colored cyan, ubiquitin wheat, the RING domain 
orange and the additional component yellow. b | Structure of dimeric RNF4-
UBE2D1–ubiquitin complex (PDB 4AP4). Loops L1 and L2 and α1 from UBE2D1, 
which bind the RING domain, and α2 of UBE2D1, which binds ubiquitin, are 
indicated. One RNF4 subunit is colored orange, the second yellow, UBE2D1 cyan 
and ubiquitin wheat. Zinc atoms are shown as grey spheres. c | Close-up view of the 
linchpin Arg in b with colors as in b. Arg181 forms hydrogen bonds with the 
sidechain of Gln40 and carbonyl oxygen of Arg72 of ubiquitin and carbonyl oxygen 
of Gln92 of UBE2D1. This interaction stabilizes ubiquitin in the closed conformation. 
d | Close-up view of UBE2D1–ubiquitin active site in b. The catalytic cysteine of 
UBE2D1 was mutated to a lysine to generate a stable amide linkage with the C-
terminus of ubiquitin to enable crystallization of the complex.  e | Additional 
ubiquitin-binding components that stabilize E2~ubiquitin in the closed conformation. 
Left panel, Tyr193 from the C-terminus of the second subunit of RNF4 packs against 
ubiquitin. Middle left panel, phospho-Tyr363 and the linker helix region (LHR) of 
CBL-B contact ubiquitin. Middle right panel, loops adjacent to the RING domain in 
RNF38 bind ubiquitin. Right panel, residues from the C-terminal helix of the second 
subunit of TRIM25 pack against ubiquitin. RING domains are colored orange, non-
RING components yellow and ubiquitin wheat. f | Additional E2-E3 interactions 
involving the backside of E2. Left to right: UBE2G2-gp78 complex (PDB: 3H8K), 
UBC7-Cue1p complex (PDB: 4JQU), RAD6-RAD18 complex (PDB: 2YBF), 
RNF38-UBE2D2–Ub-Ub complex (PDB: 4V3L) and UBE2D2-AO7 complex (PDB: 
5D1K). E2 is colored in cyan, E2 backside-binding component is in pink, ubiquitin is 
in wheat and RING domain is in orange. 
 
Figure 4. Mechanism of ubiquitin transfer by HECT E3s. a–c | Conformational 
flexibility of HECT domains. Structural alignment based on the N-lobe of HECT 
domains from WWP1 (a, PDB: 1ND7), SMURF2 (b, PDB: 1ZVD) and E6AP bound 
to the E2 UBE2L3 (c, PDB: 1C4Z) reveals different C-lobe conformations. N-lobes 
are colored orange, C-lobes magenta and UBE2L3 cyan. Arrows indicate the flexible 
hinge loop. Catalytic cysteines are shown as yellow spheres. The distance between E2 
and E3 catalytic cysteines observed in the structure is indicated in c. d | Structure of 
NEDD4L HECT-UBE2D2–ubiquitin complex (PDB: 3JVZ). UBE2D2–ubiquitin 
linkage (indicated) and C-lobe’s catalytic cysteine are juxtaposed allowing 
transthiolation of ubiquitin from the active site of the E2 to the catalytic cysteine of 
E3. Colors are as in a–c with ubiquitin colored wheat. e | Structure of NEDD4 HECT 
domain following transthiolation (PDB: 4BBN). In this case NEDD4 is bound to two 
ubiquitin molecules, one which is a covalently attached to the catalytic cysteine in the 
C-lobe following transthiolation (shown in wheat) and a second one which is non-
covalently bound to the N-lobe that enhances the processivity of substrate 
ubiquitylation (shown in lime). Colors are as in a–c. f | Structure of Rsp5(E3)–
ubiquitin-Sna3 peptide(substrate) complex (PDB: 4LCD). The catalytic Cys777 of 
Rsp5, Gly75 of ubiquitin and Lys125 of the Sna3 peptide are covalently linked via a 
three-way chemical cross-linker to mimic substrate ubiquitylation. Colors are as in a–
d with Sna3 peptide colored green and the WW3 domain grey. The disordered N-lobe 
loop harboring Asp495 is depicted as a dashed line. In d, e and f right panel, 
alignment of the three structures using the N-lobe reveals different C-lobe 
conformations in E2-E3 transthiolation and substrate ubiquitylation reactions. g | 
Schematic diagrams showing the HECT E3 catalytic cycle. In the absence of any 
binding partner, the C-lobe can rotate relative to the N-lobe about the hinge loop. 
Upon encountering E2~ubiquitin, the N-lobe binds E2 and the C-lobe rotates to bind 
ubiquitin, thereby juxtaposing the catalytic cysteines from E2 and E3. Upon ubiquitin 
transfer, E2 is released. E3 binds substrate and the C-lobe undergoes rotation to 
juxtapose E3’s catalytic cysteine and substrate lysine for ligation. Colors are as in a–f. 
 
Figure 5. Mechanism of ubiquitin transfer by RBR E3s. a,b | Structures of 
autoinhibited PARKIN (PDB: 5C23) and HHARI (PBD: 4KBL), respectively. 
Schematic diagrams above show domain architecture with structural domains colored 
according to the diagrams. Zinc atoms and RING2’s catalytic cysteines are shown as 
grey and yellow spheres, respectively. c,d | Structures of PARKIN and HHARI in a 
and b, respectively, with a modeled E2 in cyan generated by overlaying their RING1 
domain with the structure of RNF38 RING domain bound to E2 (PDB: 4V3L). Colors 
are as in a. Distances between E2 and E3’s catalytic cysteines are indicated. e | 
Structure of HOIP RBR domain bound to UBE2D2–ubiquitin (PDB: 5EDV). HOIP 
was crystallized as a domain swapped dimer, but the biological unit of HOIP-
UBE2D2-ubiquitin complex is shown here. A schematic diagram shows crystallized 
HOIP construct’s domain architecture. Structural domains are colored according to 
this diagram. UBE2D2 is colored cyan, ubiquitin wheat and ubiquitinAllo yellow. E2–
ubiquitin linkage and RING2’s catalytic cysteines are shown as yellow spheres. In a, 
b and e, the helical extension (hE) comprises two segments, hE1 and hE2 (indicated in 
the structures), which are involved in binding ubiquitin. f | Structure of HOIP together 
with acceptor ubiquitin (green, serving as substrate) and a second donor ubiquitin 
molecule (wheat) generated via crystallographic symmetry (PDB: 4LJO). Top panel is 
in the same orientation as in e. g | HOIP catalytic cycle. Binding of a ubiquitin 
molecule to the allosteric site (UbAllo) primes HOIP’s RBR conformation for 
E2~ubiquitin recruitment. The E2~ubiquitin thioester and RING2’s catalytic cysteine 
are juxtaposed for RING2~ubiquitin formation. Upon formation of the 
RING2~ubiquitin, E2 is released. Subsequently, RING2 binds an acceptor ubiquitin 
(UbAcc) and catalyzes linear ubiquitin chain formation. To catalyze additional rounds 
of ubiquitin transfer, linear ubiquitin must be released to enable E2~ubiquitin 
recruitment. 
 
Figure 6. Mechanisms of substrate lysine selection. a | A schematic drawing of 
Rsp5-catalyzed substrate ubiquitylation. Rsp5~ubiquitin presents its N- and C-lobes 
and WW3 domain in a conformation where the distance is 25 Å between the 
Rsp5~ubiquitin thioester and the substrate binding site in the WW3 domain. In this 
way, lysines at least 10 residues away from the WW3-binding motif PY in the 
substrate are prioritized for ubiquitylation. The N-lobe is colored orange, the C-lobe 
magenta, the WW3 domain grey, ubiquitin wheat and substrate in green. b | Structure 
of RNF2-BMI1-UBE2D3 complex bound to nucleosome core particle (NCP) (PDB: 
4R8P). RNF2 is colored orange, BMI1 yellow, UBE2D3 cyan, H2A green, H2B blue, 
H3 pink, H4 purple and DNA grey. H2A’s Lys119, the target for monoubiquitylation 
in this reaction, is shown as a black sphere and UBE2D3’s catalytic cysteine is shown 
as a yellow sphere. The interactions between the RNF2-BMI1-UBE2D3 complex and 
NCP restrain UBE2D3 and H2A movement such that UBE2D3’s catalytic cysteine 
can only be juxtaposed with H2A’s Lys119 for site-specific ubiquitylation. c | 
Schematic drawings of APC/C-catalyzed substrate ubiquitylation. APC11 binds 
UBE2C~ubiquitin via the canonical RING E3-E2~ubiquitin interaction shown in 
Figure 3 and APC2’s WHB domain contacts UBE2C’s backside. These bipartite 
interactions fix the UBE2C~ubiquitin orientation such that the thioester bond is ~40 Å 
away from the D and KEN box binding sites on the substrate-receptor CDH1, thereby 
prioritizing substrate lysines located 10 residues away from these motifs for 
ubiquitylation. Once the substrate is modified with a single ubiquitin, APC/C tracks 
the tip of the growing ubiquitin chain. APC11 binds the acceptor ubiquitin (colored in 
lime) using a surface distinct from its E2~ubiquitin-binding site and presents the 
acceptor ubiquitin to a UBE2S~ubiquitin complex for ubiquitin chain elongation. 
APC/C is shown as an outline. APC11 is colored orange, UBE2C and UBE2S cyan, 
ubiquitin wheat, APC2 and WHB light blue and CDH1 grey. Green ribbons depict 
binding sites on CDH1 for substrates containing a D- or KEN-box.  
 
Figure 7. Mechanisms of autoinhibition and activation of E3s. a | Schematic 
showing domain composition of cIAP1 (top) and the mechanism of its autoinhibition 
and activation (bottom). In solution, cIAP1 adopts a closed conformation where the 
E2~ubiquitin binding and dimerization surfaces of the RING domain are occluded. 
SMAC mimetic compound binds the BIR3 domain and shifts cIAP1 to an extended 
conformation. This enables RING domain dimerization which is critical for binding 
and priming E2~ubiquitin for catalysis. b | Schematic showing domain composition of 
SMURF2 (top) and the mechanism of its autoinhibition and activation (bottom). The 
C2 domain of SMURF2 binds both the N- and C-lobes of the HECT domain, thereby 
preventing rotation of the two lobes and blocking non-covalent ubiquitin binding. 
Addition of SMAD7 or other stimuli causes the release of the C2 domain, thereby 
facilitating E2-E3 transthiolation and non-covalent ubiquitin binding important for 
processive substrate ubiquitylation. c | Schematic drawings showing domain 
composition of PARKIN (top) and the mechanism of its autoinhibition and activation. 
PARKIN adopts an autoinhibited conformation where the E2~ubiquitin binding site 
on RING1 and catalytic cysteine of RING2 are blocked. Moreover, in this 
conformation the catalytic cysteine of RING2 is distal from the modeled catalytic 
cysteine of E2 as shown in Figure 5c. Addition of phospho-Ser65-ubiquitin (shown as 
pUb in the drawing) and phosphorylation of PARKIN’s Ser65 in the UBL domain 
(shown as a red ball and stick) synergistically activate PARKIN. The phosphorylated 
UBL domain is released from the RING1 domain, partially freeing the E2~ubiquitin 
binding surface. Phospho-Ser65-ubiquitin then binds a pocket created by RING0, 
RING1, hE and IBR and induces straightening of hE similar to that observed in the 
HOIP-UBE2D2–ubiquitin structure (Figure 5e,g). Notably, PARKIN’s RING1-hE-
IBR-phospho-Ser65-ubiquitin complex adopts a conformation that resembles RING1-
hE-IBR-ubiquitinAllo in the HOIP-UBE2D2–ubiquitin structure, suggesting a similar 
mechanism in E2~ubiquitin recruitment of both enzymes, though this remains to be 
investigated. For all panels, domain architectures are shown and colored according to 
the schematic. d | Crystal structure of PARKIN bound to phospho-Ser65-ubiquitin 
(PDB: 5CAW). Structural domains are colored according to the schematic drawing in 
c. Phospho-Ser65-ubiquitin is in yellow with pSer65 indicated. RING2’s catalytic 
cysteine is shown as a yellow sphere.  
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Key points 
• E3s recruit E2~ubiquitin (~ denotes a thioester linkage between E2’s catalytic 
cysteine and the C-terminus of ubiquitin) and substrate to promote ubiquitin 
transfer. Mechanisms of E3 catalysis and regulation are summarized here. 
• Crystal structures and NMR studies reveal that RING E3s prime E2~ubiquitin 
for transfer by promoting a closed E2~ubiquitin conformation where the 
thioester is activated toward nucleophilic attack. 
• Crystal structures of HECT E3s in different stages of catalysis reveal that 
conformational changes juxtapose reactants to prime ubiquitin transfer. 
• Crystal structures reveal how RBR E3s are autoinhibited. Upon activation, 
crystal structures of RBR E3s bound to E2~ubiquitin show how ubiquitin is 
transferred from E2 to E3 and subsequently to substrate. 
• Substrate lysine selection and the outcome of ubiquitylation depends on 
spatial arrangements within E2-E3-substrate complexes. Substrate lysines that 
are in proximity to the active sites of E2 or E3 are prioritized for ligation. 
• E3s are regulated by various autoinhibitory mechanisms that hinder their 
catalytic cycle. Activation frequently requires post-translational modification 
or binding of protein partners or substrates. 
 
  
Glossary 
ε-amino group 
Refers to the NH3+ group in a lysine sidechain. It has a high pKa and often the active 
site environment(s) of E2, E3 or substrate can assist in lowering its pKa to increase its 
reactivity. 
  
26S proteasome 
A large protein complex that degrades proteins modified with ubiquitin chains. It 
contains a 20S core particle that accommodates the protease catalytic subunits and 
two 19S regulatory subunits that recognize ubiquitylated substrates and facilitate 
substrate unfolding prior to entry into the 20S core particle. 
 
Anaphase promoting complex/cyclosome (APC/C) 
A multi-subunit RING E3 complex that plays a central role in cell cycle progression 
by ubiquitylating cell cycle proteins and targeting them for degradation.   
 
PY motif 
A short proline-rich motif containing a proline-proline-x-tyrosine (x is any amino 
acid) sequence that is recognized by a WW domain. 
 
NMR 
(Nuclear magnetic resonance). A technique that provides detailed information about 
protein structure and dynamics in solution. 
 
Allosteric change 
Refers to changes induced in one part of a molecule, usually an enzyme’s active site, 
by a distal binding event. 
 
SAXS 
(Small angle X-ray scattering). A technique where the elastic scattering of X-rays by 
a protein in solution is used to provide information about the protein’s shape and size. 
 
C-terminal tail of ubiquitin 
Residues 71-76 of ubiquitin 
 
SUMO 
A ubiquitin-like protein modifier that has its own dedicated E1-E2-E3 enzymatic 
cascade for modification of protein substrates. 
 
α-amino group 
Refers to the NH3+ group connected to the α-carbon in an amino acid.  In proteins, it 
is only present at the N-terminus because it is otherwise involved in forming an amide 
link with an adjacent amino acid. Under cellular condition, it exists in the protonated 
NH3+ form and requires deprotonation to increase its reactivity. 
 
Nucleosome core particle (NCP) 
A basic repeating unit of DNA packaging found in eukaryotes. A single NCP contains 
147 base pairs of DNA wrapped around a histone octamer consisting two histone 
H2A-H2B dimers and a histone H3-H4 tetramer. 
 
NF-κB signalling 
A signalling pathway that activates NF-κB in response to stimuli including 
proinflammatory cytokines, bacterial and viral infections, and antigen receptor 
binding. Activated NF-κB leads to expression of genes that are regulators of 
apoptosis, cell survival, proliferation and immunity.  
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